196 related articles for article (PubMed ID: 2727464)
1. Surrogate endpoints in clinical trials: cancer.
Ellenberg S; Hamilton JM
Stat Med; 1989 Apr; 8(4):405-13. PubMed ID: 2727464
[TBL] [Abstract][Full Text] [Related]
2. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
3. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
4. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
5. Novel procedures for validating surrogate endpoints in clinical trials.
Cleophas TJ; Zwinderman AH; Chaib AH
Curr Clin Pharmacol; 2007 May; 2(2):123-8. PubMed ID: 18690859
[TBL] [Abstract][Full Text] [Related]
6. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints in clinical trials: definition and operational criteria.
Prentice RL
Stat Med; 1989 Apr; 8(4):431-40. PubMed ID: 2727467
[TBL] [Abstract][Full Text] [Related]
8. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
9. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
10. Surrogate endpoints in clinical trials: cardiovascular diseases.
Wittes J; Lakatos E; Probstfield J
Stat Med; 1989 Apr; 8(4):415-25. PubMed ID: 2727465
[TBL] [Abstract][Full Text] [Related]
11. Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs.
Huang Y; Yuan J
Expert Rev Clin Pharmacol; 2024; 17(5-6):477-487. PubMed ID: 38632893
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers as surrogate endpoints in cancer trials.
Dunn BK; Akpa E
Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317
[TBL] [Abstract][Full Text] [Related]
13. Innovative Thinking on Endpoint Selection in Clinical Trials.
Chow SC; Huang Z
J Biopharm Stat; 2019; 29(5):941-951. PubMed ID: 31454270
[TBL] [Abstract][Full Text] [Related]
14. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
15. A rank test for bivariate time-to-event outcomes when one event is a surrogate.
Shaw PA; Fay MP
Stat Med; 2016 Aug; 35(19):3413-23. PubMed ID: 27059817
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.
Colloca G
Cancer Treat Rev; 2012 Dec; 38(8):1020-6. PubMed ID: 22503300
[TBL] [Abstract][Full Text] [Related]
17. Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review.
Branchoux S; Bellera C; Italiano A; Rustand D; Gaudin AF; Rondeau V
Crit Rev Oncol Hematol; 2019 May; 137():35-42. PubMed ID: 31014514
[TBL] [Abstract][Full Text] [Related]
18. The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process.
Redmond K
Eur J Cancer; 1997 Jan; 33 Suppl 2():S11-3. PubMed ID: 9166090
[TBL] [Abstract][Full Text] [Related]
19. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Oxnard GR; Morris MJ; Hodi FS; Baker LH; Kris MG; Venook AP; Schwartz LH
J Natl Cancer Inst; 2012 Oct; 104(20):1534-41. PubMed ID: 22927506
[TBL] [Abstract][Full Text] [Related]
20. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
